General Updates

To To Date: 07/09/2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Allotment of 10,00,000 Warrants to the Promoter of the Company on Preferential Basis Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, This is in continuation of the earlier intimations made by the Company in connection with the proposed issue of Convertible Warrants on a preferential basis. Pursuant to the Regulation 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with relevant circulars thereto issued by Securities and Exchange Board of India from time to time (“SEBI Listing Regulations”) and in compliance with the Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and approval accorded by the Shareholders of Bal Pharma Limited (“the Company”) through Postal Ballot on 08th August, 2026 and In-Principle approval granted by the National Stock Exchange of India Limited (vide its letter bearing reference no NSE/LIST/56262) and BSE Limited (vide its letter bearing reference no LOD/PREF/GB/FIP/749/2026-27) on 04th September 2026, and upon receipt of ₹2,10,00,000/- (Rupees Two Crores Ten Lakhs only) i.e. the 25% of the total amount payable towards subscription of the warrants from the allottee, we wish to inform that the Board of Directors of the Company vide their Resolution passed through Circulation (01/2026-27) today i.e. Monday, 07th September, 2026 has considered , approved and Confirmed the allotment of 10,00,000 (Ten Lakh) Warrants on a preferential basis to Mr. Shailesh Siroya, Promoter of the Company, at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/- (Rupees Eight Crore Forty Lakh only), on such terms and conditions as approved by the Members and in accordance with the applicable provisions of law. Further, the aforesaid warrant(s) are being allotted in electronic form and are subject to lock-in, in compliance with the applicable provisions of SEBI ICDR Regulations. The conversion of warrants into equivalent number of equity shares of the Company can be exercised by the warrant holder at any time during the period of eighteen months from the date of allotment of Warrants i.e. 07th September 2026, in one or more tranches, upon payment of the remaining 75% of the amount payable against each such warrant before the last date of conversion of warrants. Since the Company has allotted Convertible Warrants and not Equity Shares, there is no change in the paid-up Equity Share Capital of the Company pursuant to the aforesaid allotment of Warrants. Upon exercise of the Warrants and payment of the balance consideration, the corresponding Equity Shares shall be allotted by the Company and shall rank pari passu in all respects with the existing Equity Shares of the Company. The Equity Shares to be allotted upon conversion of the Warrants shall be listed on BSE Limited and National Stock Exchange of India Limited, where the existing Equity Shares of the Company are listed, subject to receipt of the requisite approvals from the respective Stock Exchanges and compliance with applicable laws and regulations. The details in respect of the preferential issue, as required to be disclosed under Regulation 30 of the SEBI Listing Regulations, read with the SEBI Master Circular is set out below in Annexure – A. Kindly take the above information on record. Thanking You. For Bal Pharma Ltd Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 Enclosure: Annexure A Annexure-A Details required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular Sl No Particulars Details 1 Type of securities Convertible warrants proposed to be issued 2 Type of issuance Preferential issue 3 Total number of securities 10,00,000 (Ten Lakh) Warrants at an issue price of proposed to be issued or the total ₹84/- (Rupees Eighty-Four only) per Warrant, amount for which the securities will aggregating to ₹8,40,00,000/- (Rupees Eight Crore be issued Forty Lakh only). Each Warrant is convertible into, or exchangeable for 1 (One) equity share of the Company of face value Rs. 10 (Rupees Ten only) at a premium of Rs. 74 (Rupees Seventy-Four only) per share. 4 Additional Information in case of preferential issue: a Name of investor Mr. Shailesh Siroya, Promoter of the Company b Post allotment of securities Warrants are allotted to the following Allottee. outcome of the subscription Details of the shareholding of the Allottee in the Company, prior to and after the proposed preferential issue, are as under: Particulars Pre- Post- (Name of Preferential Allotment of the Allotment Warrants Investors) pursuant to Preferential Issue * Mr. Shailesh 27,45,459 37,45,459 Siroya (17.24%) (20.89%) * The above shareholding has been arrived at on the assumption that the entire 10,00,000 Warrants allotted would be converted into Equity Shares c Issue Price/ allotted ₹84/- (Rupees Eighty-Four only) per Warrant. price (in case of (including the warrant subscription price and convertibles) exercise price) d Number of Investors 01 (One) e In case of Convertibles intimation Each Warrant will be convertible into, or on conversion of securities or on exchangeable for 1 (One) fully paid-up equity share lapse of the tenure of the of the Company of face value of Rs. 10 (Rupees Ten instrument only), which may be exercised in one or more tranches during a period of 18 (eighteen) months commencing from the date of allotment of the Warrants i.e. 07th September 2026. In the event the Allottee does not exercise the Warrants within the aforesaid period, the unexercised Warrants shall lapse and the amount paid by the Allottee on the unexercised Warrants shall stand forfeited on such terms and conditions as approved by the Members and in accordance with the applicable provisions of law. For Bal Pharma Ltd Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681